January 16, 2023
A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.
January 11, 2023
A recent study found that while children exposed to benzodiazepine during pregnancy had a greater risk of developing autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), siblings without exposure saw similar risks of neurodevelopmental disorders.
December 27, 2022
Lisdexamfetamine dimesaylate was associated with reduced ADHD symptoms in children aged 4 to 5 years.
December 20, 2022
Robert L. Findling, MD, MBA; and Timothy Wilens, MD, share advice on the treatment of pediatric ADHD and new agents in the pipeline.
December 20, 2022
Drs Robert L. Findling and Timothy Wilens discuss the efficacy and safety data of serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) in childhood ADHD.
December 20, 2022
Robert L. Findling, MD, MBA, and Timothy Wilens, MD, review serdexmethylphenidate-dexmethylphenidate, a combination agent recently approved for the treatment of ADHD.
December 20, 2022
Jeffrey L. Alvaro, M.D., introduces an upcoming panel discussion surrounding the clinical implications of novel drug delivery systems in the management of Pediatric ADHD, utilizing 3 patient cases.
December 13, 2022
Robert L. Findling, MD, MBA, and Timothy Wilens, MD, consider the dosing and adherence challenges that arise in pediatric ADHD, as well as the potential benefits and damages of patients taking a break from treatment.
December 13, 2022
Experts in psychiatry discuss strategies for titrating to optimal doses for patients with pediatric ADHD.
December 06, 2022
MRI studies have associated white matter bundles with greater severity of ADHD symptoms.